The National Cancer Institute's Affordable Cancer Technologies (ACTs) Program marks a decade of success in supporting translational research. This initiative focuses on delivering affordable, scalable cancer prevention and control solutions for low- and middle-income countries. The program has funded 38 grants resulting in patents, publications, and the adoption of novel approaches, including point-of-care diagnostics for colorectal cancer and HPV, and new technologies for chemotherapy surveillance and cervical precancer treatment. ACTs accelerate life-saving innovations from the lab to real-world communities.
Pearlman et al. (Thu,) studied this question.